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plantation, Grosso et al. report encouraging outcomes after
adopting a 2-step approach to myeloablative haploidentical
transplantation in 30 patients with early-stage hematologi-
cal malignancies [1]. Lymphoid and myeloid portions of the
graft were administered separately to control T cell dosing.
Donors ﬁrst underwent apheresis to provide a ﬁxed dose of
2  108/kg CD3þ cells, they received 5 days of granulocyte
colonyestimulating factor (G-CSF), and then they underwent
additional aphereses for hematopoietic stem cells and CD34þ
cell selection. After 12 Gy total body irradiation, patients
received the ﬁxed dose of T cells and, 2 days later, cyclo-
phosphamide to establish bidirectional tolerance. The
myeloid portion of the graft was given 24 hours after
completion of cyclophosphamide. The 2-year cumulative
incidences of grade II to IV and III to IV acute graft-versus-
host disease (GVHD) were 39.3% and 3.6%, respectively. No
patient died of GVHD or infection. Six patients relapsed and 5
died. The 2-year probability of disease-free survival was 74%,
conﬁrming previous data by the same authors [2]. These
outcomes are extremely encouraging.
Bone marrow transplantation centers are becoming more
and more interested in haploidentical transplantation, as it
offers the advantages of immediate donor availability for
almost all patients and access to donor-derived immune cell
therapies after transplantation. The 1990s saw what had
been major drawbacks, ie, very strong host-versus-graft and
graft-versus-host alloresponses, which led to rejection and
GVHD, respectively, being overcome through the use of high-DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.12.019.
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http://dx.doi.org/10.1016/j.bbmt.2015.02.004intensity conditioning regimens and transplantation of a
mega-dose of extensively T celledepleted peripheral blood
hematopoietic progenitor cells [3]. T cell depletion, however,
delayed immune reconstitution andwas associatedwith high
transplantation-related/infectious mortality rate. On the
other hand, post-transplantation immune recovery in the
absence of any immune suppression created an opportunity
for discovering innovative forms of immunotherapy. It
favored natural killer cell development and revealed donor-
versus-recipient natural killer cell alloreactions, which erad-
icated acute myeloid leukemia and improved survival [4]. It
also allowed effective donor T cell immunotherapies (devoid
of GVHD potential) that protected against infections
(reviewed in [5]). The setting provided evidence that infusion
of donor regulatory T cells (Treg) efﬁciently protected against
otherwise lethal doses of conventional T cell (Tcon) add-
backs. The Treg/Tcon add-back greatly reduced the relapse
rate by strengthening the graft-versus-leukemia effects [6].
In the ﬁeld of haploidentical transplantation, recent ap-
proaches have used noneT celledepleted (“unmanipulated”)
grafts combined with new strategies to attenuate/modulate
donor T cell alloreactivity and help prevent GVHD. For
example, after infusion of unmanipulated grafts, an appre-
ciably low GVHD rate in 45 patients with advanced hemato-
logical malignancies was achieved by exploiting the immune
regulatory effect of rapamycin to prevent GVHD [7]. The
Huang group ﬁrst applied G-CSF priming of unmanipulated
haploidentical blood and marrow grafts and intensive post-
transplantation immune suppression to modulate/down-
regulate donor T cell alloreactivity [8]. Using G-CSFeprimed
bone marrow, Di Bartolomeo et al. achieved very encouraging
3-year probabilities of overall and disease-free survival
for standard-risk, and even high-risk, patients [9]. In a
different approach, low risk of acute and chronic GVHD and
encouraging rates of transplantation-related mortality were
observed after unmanipulated haploidentical bone marrow
transplantation and post-transplantation high-dose cyclo-
phosphamide [10,11].
In the present paper [1], Grosso et al. gave 2 separate
inocula: T cells followed by cyclophosphamide to attenuate T
cell alloreactions and subsequently administering the he-
matopoietic progenitor cell graft. The advantages of this
strategyare theﬁxedTcell doseandnoTcell exposure toG-CSF.
A. Gratwohl / Biol Blood Marrow Transplant 21 (2015) 579e582580In conclusion, recent years have witnessed acceptance of
and development of diverse approaches to haploidentical
transplantation. The original approach, transplantation of
high numbers of T celledepleted hematopoietic progenitor
cells and no post-transplantation immune suppression has,
with over 15 years’ follow-up, provided well-established
outcomes in adults and children and continues to offer
unique opportunities for innovative immunotherapeutic
strategies. All the recent reports of unmanipulated hap-
loidentical transplantation have fostered interest and debate
in the ﬁeld and, most importantly, served to substantially
extend its use. The new 2-step approach, as adopted by
Grosso et al. [1], provides very interesting results. It is to be
hoped they will be conﬁrmed in a longer follow-up and a
larger cohort of patients.
ACKNOWLEDGMENTS
Financial disclosure: The author have nothing to disclose.
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
REFERENCES
1. Grosso D, Gaballa S, Alpdogan O, et al. A two-step approach to mye-
loablative haploidentical transplantation: low nonrelapse mortality
and high survival conﬁrmed in patients with earlier stage disease. Biol
Blood Marrow Transplant. 2015;21:646-652.DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.12.018.
Financial disclosure: See Acknowledgments on page 581.
* Correspondence and reprint requests: Alois Gratwohl, MD, Dittinger-
strasse 4, CH-4053 Basel, Switzerland.
E-mail address: alois.gratwohl@unibas.ch (A. Gratwohl)
1083-8791/ 2015 American Society for Blood andMarrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.2015.02.0032. Grosso D, Carabasi M, Filicko-O’Hara J, et al. A 2-step approach
to myeloablative haploidentical stem cell transplantation: a phase 1/2
trial performed with optimized T-cell dosing. Blood. 2011;118:
4732-4739.
3. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leu-
kemia with T-cell-depleted stem cells from related donors with one
fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186-1193.
4. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural
killer cell alloreactivity in mismatched hematopoietic transplants.
Science. 2002;295:2097-2100.
5. Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic trans-
plantation: current status and future perspectives. Blood. 2011;118:
6006-6017.
6. Martelli MF, Di Ianni M, Ruggeri L, et al. HLA-haploidentical trans-
plantation with regulatory and conventional T-cell adoptive immuno-
therapy prevents acute leukemia relapse. Blood. 2014;124:638-644.
7. Ciceri F, Bregni M, Peccatori J. Innovative platforms for haploidentical
stem cell transplantation: the role of unmanipulated donor graft.
J Cancer. 2011;2:339-340.
8. Huang X-J, Liu D-H, Liu K-Y, et al. Treatment of acute leukemia with
unmanipulated HLA mismatched/haploidentical blood and bone
marrow transplantation. Biol Blood Marrow Transplant. 2009;15:
257-265.
9. Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical, un-
manipulated, G-CSF-primed bone marrow transplantation for patients
with high-risk hematologic malignancies. Blood. 2013;121:849-857.
10. Fuchs EJ. Human leukocyte antigen-haploidentical stem cell trans-
plantation using T-cell-replete bone marrow grafts. Curr Opin Hematol.
2012;19:440-447.
11. Raiola AM, Dominietto A, di Grazia C, et al. Unmanipulated
haploidentical transplants compared with other alternative donors and
matched sibling grafts. Biol Blood Marrow Transplant. 2014;20:
1573-1579.HY: Foe or Maybe Friend?Alois Gratwohl*
Department of Hematology, University of Basel, Basel, SwitzerlandArticle history:
Received 1 February 2015
Accepted 5 February 2015Kongtim et al. [1] from the department of stem cell
transplantation and cellular therapy at the MD Anderson
Cancer Center in Houston report convincing data showing
that a female donor for amale recipient can reduce the risk of
relapse after allogeneic hematopoietic stem cell trans-
plantation (HSCT) for acute myeloid leukemia. The positive
effects were most pronounced in young patients, under 50
years old, with advanced leukemia. The authors propose
considering a female donor as the preferred option in those
situations where relapse is of most concern; eg, for younger
patients with advanced disease stage or refractory disease.
They are optimistic about further studies with novel graft-
versus-host disease (GVHD) prevention methods. Such new
concepts might better exploit this speciﬁc advantage of an
HY mismatch; hence, leading to improved survival after
transplantation.The authors’ carefully conducted single-center study adds
to a long series of reports suggesting that minor histocom-
patibility antigens are as robust transplantation antigens as
their major histocompatibility antigen counterparts, the
human leukocyte antigens (HLA). HY, a group of Y chromo-
someeencoded antigens, are just among the most deﬁned
[2,3]. Multiple peptides have been identiﬁed. They can be
recognized by the host immune system and they can elicit a
humoral as well as a cellular immune response. In 1955,
Eichwald was the ﬁrst to describe a higher and faster rejec-
tion rate of male skin in female mice compared with those in
sex-identical pairs [4]. Twenty years later, Uphoff described
increased GVHD in male mice that underwent trans-
plantation with bone marrow from multiparous females
compared with those who received bone marrow from male
or nulliparous donors [5]. The importance of HYas a relevant
clinical entity in the human immune response was clearly
described by Goulmy in 1976 [6], followed by amore detailed
description of the effects of sex mismatch on rejection and
GVHD after transplantation for aplastic anemia [7].
Why then did it take more than 2 decades to establish the
role of HY for both GVHD and graft-versus-leukemia (GVL)
effects after HSCT [8] and to assess the role of HY in clinical
kidney transplantation [9,10]?Why then is gender mismatch
not integrated in the kidney donor allocation scheme [11]?
Why does the question about best donor selection in HSCT
prevail [1]?
The answer is, in part, simple. Too frequently, there is just
“only 1 donor available.” The slightly higher risk might still
